Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SGL CARBON SE. We currently have 14 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
SGL CARBON SE
SGL CARBON SE
A capital increase was imminent!
29 Nov 16
SGL Carbon has announced a capital increase to deleverage the balance sheet. The company will issue 30m new ordinary shares against cash contributions. The new bearer shares with a no par value (notional value of €2.56) will be offered to existing shareholders at a ratio of 40:13 and a subscription price of €6 per share. THe gross proceeds should reach €180m. In September 2016, the equity ratio reached only 6% and will be increased to 14.8% via the capital increase.
There is hope!
18 Nov 16
The company reported final Q3 16 numbers excluding the discontinued business Performance Products. Revenues declined 9.6% to €182.7m. EBITDA dropped 54.9% to €12.5m and the EBITDA margin declined from 13.7% to 6.8%. EBIT plummeted 95.6% to €0.3m. The EBIT margin dived from 3.4% to 0.2% despite higher operating income which increased 48% to €11.1m. Net losses including discontinued business rose from €20.6m to €50.9m. In the first nine months, adjusted revenues declined 6.1% to €526.1m. EBITDA dropped 40.7% to €42.8m and the EBITDA margin declined from 12.1% to 7.6%. Net losses increased from €102.4m to €124.1m.
Small is beautiful!
20 Oct 16
SGL Carbon has sold its loss-making business division Performance Products (PP) to the Japanese company Showa Denko for an enterprise value of around €350m cash and debt free. The company will receive at least €200m after the deduction of standard debt-like items such as pension and restructuring provisions.
Wanted: investor with deep pockets
16 Aug 16
The company reported Q2 16 results. Revenues declined 3.2% to €191.9m excluding the carved-out business division Performance Products (PP) which is now classified as held for sale and as a discontinued operation. Consequently, all assets and liabilities were adjusted for PP. The adjusted gross margin declined from 18.8% to 17.3%. EBITDA plummeted 57.7% to €14.2m but EBIT improved from a loss of €0.2m to a profit of €1.2m. Net losses excluding PP reached €6.8m and including PP around €46.8m compared to a loss of €68.5m in Q2 15. In the first half year, adjusted revenues declined 1.5% to €379.4m. EBIT improved from a loss of €3.3m to a profit of €6.3m. Net losses including PP reached €73.2m compared to €85m in the first half year 2015.
Keeping fingers crossed
30 May 16
According to the latest news, the Chinese State-owned company ChemChina may be interested in buying the ailing Performance Products business from SGL Carbon or even the whole company. The management of SGL Carbon has already circulated the offering prospectus for the Performance Products business division. Now a serious buyer has turned up and shown interest in the company.
Every dime is needed to push up EBIT
12 May 16
The company reported final Q1 16 results. Revenues declined 6.5% to €294.7m and EBIT turned from a small profit of €4.3m to a loss of €6.8m. According to the company, EBIT losses reached €5.3m due to a change in EBIT calculation. Net losses increased from €16.5m to €26.4m.
20 Feb 17
Hayward Tyler Group* (HAYT): Trading update and financial position (CORP) | Petra Diamonds (PDL): Interim results (BUY) | Gemfields* (GEM): Interim results (CORP) | Premaitha Health* (NIPT): Middle East momentum (CORP) | Sound Energy (SOU): Acquisition update and TE-8 well spud (HOLD) | Proactis* (PHD): Interim trading on track (CORP) | 7digital* (7DIG): Automotive contract win (CORP)
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
N+1 Singer - Small-cap quantitative research - New quality style screen + 11 quality focus stocks
09 Feb 17
We introduce our fourth and final style screen representing “quality”. This screens for stocks with the best combination of high returns on capital/equity, EBIT margins and operating cash-flow conversion rates. These criteria should help us monitor how strong underlying returns translate into share price performance over time and under varying market conditions. The screen selects the “best” 25 stocks from our universe of just over 500 stocks and, as usual, we focus on a shorter list of stocks we cover or otherwise know and believe to be particularly interesting. We provide brief investment summaries on these focus stocks on pages 4 – 9. We will monitor performance and refresh the screen in approximately 3-4 months time.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
Small Cap Breakfast
16 Feb 17
Saffron Energy—Schedule One update. Raising £2.5m, expected Mkt Cap £7.7m. Admission due 24 Feb. Italian Oil & Gas Play Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime. Issue closing 23 Feb. Arix Bioscience — Intention to float on the main market from the global healthcare and life science Company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management